| 9.78 0.05 (0.51%) | 09-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 12.02  |
1-year : | 12.81 |
| Resists | First : | 10.29 |
Second : | 10.97 |
| Pivot price | 9.68 |
|||
| Supports | First : | 9.19 | Second : | 7.65 |
| MAs | MA(5) : | 9.75  |
MA(20) : | 9.77 |
| MA(100) : | 10.24 |
MA(250) : | 11.56 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 66.6 |
D(3) : | 57.4 |
| RSI | RSI(14): 46.2 |
|||
| 52-week | High : | 14.63 | Low : | 9.19 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ DVAX ] has closed below upper band by 34.9%. Bollinger Bands are 52.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 2 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 9.83 - 9.88 | 9.88 - 9.92 |
| Low: | 9.51 - 9.56 | 9.56 - 9.61 |
| Close: | 9.7 - 9.78 | 9.78 - 9.86 |
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; agreement with Serum Institute of India Pvt. Ltd.; and sublicense agreement with Merck, Sharp & Dohme Corp. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.
Tue, 23 Sep 2025
Dynavax Technologies (DVAX): Evaluating Valuation After CDC Panel Delays MMRV Vaccine for Young Children - simplywall.st
Sun, 21 Sep 2025
How Investors Are Reacting To Dynavax Technologies (DVAX) Amid Regulatory Scrutiny Over Child Vaccine Access - Sahm
Tue, 16 Sep 2025
Dynavax Technologies Corporation $DVAX Shares Purchased by Woodline Partners LP - MarketBeat
Mon, 15 Sep 2025
Jacobs Levy Equity Management Inc. Buys New Position in Dynavax Technologies Corporation $DVAX - MarketBeat
Tue, 02 Sep 2025
Dynavax Technologies Corporation (DVAX) Reports Record $92M HEPLISAV-B Revenue, Raises 2025 Outlook - Yahoo Finance
Wed, 27 Aug 2025
Vaccine Developer Dynavax to Showcase HEPLISAV-B and COVID-19 Programs at Wells Fargo Conference - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 117 (M) |
| Shares Float | 101 (M) |
| Held by Insiders | 0.6 (%) |
| Held by Institutions | 97.9 (%) |
| Shares Short | 14,100 (K) |
| Shares Short P.Month | 14,490 (K) |
| EPS | -0.45 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.21 |
| Profit Margin | -16.7 % |
| Operating Margin | 17.4 % |
| Return on Assets (ttm) | 0.5 % |
| Return on Equity (ttm) | -9.3 % |
| Qtrly Rev. Growth | 29.2 % |
| Gross Profit (p.s.) | 1.73 |
| Sales Per Share | 2.69 |
| EBITDA (p.s.) | 0.11 |
| Qtrly Earnings Growth | 76 % |
| Operating Cash Flow | 76 (M) |
| Levered Free Cash Flow | 43 (M) |
| PE Ratio | -21.74 |
| PEG Ratio | 0 |
| Price to Book value | 2.31 |
| Price to Sales | 3.62 |
| Price to Cash Flow | 15.03 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|